b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Rajasthan Public Service Commission has released RPSC RAS Recruitment 2026 notification. The Rajasthan State and Sub. Services Comb. Comp Exam 2026 registration process will begin on June 4 and will ...

A licensed attorney with nearly a decade of experience in content production, Valerie Catalano knows how to help readers digest complicated information about the law in an approachable way. Her ...

Doha, Qatar: As Qatar continues advancing its knowledge-based economy ambitions under Qatar National Vision 2030, graduates of the Executive MBA programme at HEC Paris, Doha, say their programme ...

RAS mutations are among the most common drivers in cancer, particularly in pancreatic, colorectal, and lung tumors. Despite that, directly targeting RAS proteins proved extremely difficult for years, ...

Editor’s Note: This article is purely satirical and fictitious. All attributions in this article are not genuine, and this story should be read in the context of pure entertainment only. After current ...

DOHA: HEC Paris, ranked among the world’s top business schools, invites professionals in Qatar to an online Info Session on its Executive MBA Emerging Leaders Track. The session will be led by Dr ...

I drank an inordinate amount of jungle juice at my first Stanford party. Early into my second quarter on campus, I had no real thoughts beyond the desire to forget the mistakes I made the quarter ...

Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space. BridgeBio ...

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...